- Home
- GRI vs SGD Comparison
GRI vs SGD Comparison
Compare GRI & SGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- SGD
- Stock Information
- Founded
- GRI 2018
- SGD 2021
- Country
- GRI United States
- SGD United States
- Employees
- GRI N/A
- SGD N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- SGD
- Sector
- GRI Health Care
- SGD
- Exchange
- GRI Nasdaq
- SGD Nasdaq
- Market Cap
- GRI 4.8M
- SGD 4.4M
- IPO Year
- GRI N/A
- SGD N/A
- Fundamental
- Price
- GRI $1.98
- SGD $1.29
- Analyst Decision
- GRI Strong Buy
- SGD
- Analyst Count
- GRI 2
- SGD 0
- Target Price
- GRI $22.50
- SGD N/A
- AVG Volume (30 Days)
- GRI 417.8K
- SGD 314.3K
- Earning Date
- GRI 11-13-2025
- SGD 11-22-2025
- Dividend Yield
- GRI N/A
- SGD N/A
- EPS Growth
- GRI N/A
- SGD N/A
- EPS
- GRI N/A
- SGD N/A
- Revenue
- GRI N/A
- SGD $1,536,255.00
- Revenue This Year
- GRI N/A
- SGD N/A
- Revenue Next Year
- GRI N/A
- SGD N/A
- P/E Ratio
- GRI N/A
- SGD N/A
- Revenue Growth
- GRI N/A
- SGD 1570.24
- 52 Week Low
- GRI $1.10
- SGD $0.65
- 52 Week High
- GRI $30.43
- SGD $6.00
- Technical
- Relative Strength Index (RSI)
- GRI 54.39
- SGD 49.65
- Support Level
- GRI $1.86
- SGD $1.20
- Resistance Level
- GRI $2.05
- SGD $1.55
- Average True Range (ATR)
- GRI 0.13
- SGD 0.17
- MACD
- GRI -0.02
- SGD -0.02
- Stochastic Oscillator
- GRI 25.62
- SGD 44.44
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.